Pharmacology, Toxicology and Pharmaceutical Science
Pancreas Cancer
71%
Malignant Neoplasm
47%
Nanoparticle
43%
Pancreas Adenocarcinoma
40%
Immune Checkpoint Inhibitor
40%
Pancreas Tumor
30%
Hematoporphyrin
30%
Randomized Controlled Trial
20%
Antioxidant Capacity
20%
Polyphenol
20%
Solid Lipid Nanoparticle
20%
Small Interfering RNA
20%
Hypoxia
20%
Gemcitabine
20%
Vasopressin Receptor
20%
Argipressin
20%
Cathepsin B
20%
Ascophyllum
20%
Tumor Model
20%
Reactive Oxygen Metabolite
17%
Cytotoxicity
13%
MF1 Mouse
10%
Cuniculidae
10%
Phloroglucinol
10%
Sulfate
10%
Bioavailability
10%
Liver Injury
10%
Biodistribution
10%
Immunosuppressive Agent
10%
Copolymer
10%
Monotherapy
10%
Glutamic Acid
10%
Side Effect
10%
Photodynamic Therapy
10%
CD8 Antigen
9%
Cytokine
8%
Flow Cytometry
8%
Monoclonal Antibody
6%
Tumor Growth
6%
Bilateral Cancer
6%
Immunoglobulin
6%
Receptor
6%
Dimer
6%
C Reactive Protein
6%
Maltodextrin
6%
Biological Marker
6%
Placebo
6%
Glucuronide
6%
Rose Bengal
5%
Tumor Microenvironment
5%
Medicine and Dentistry
Tumor
100%
Sonodynamic Therapy
89%
Pancreas Cancer
66%
Nanoparticle
52%
Programmed Death-Ligand 1
40%
Beta Cell
25%
Immune Checkpoint Inhibitor
24%
Diabetes
22%
Glucagon
22%
Gemcitabine
20%
Hypoxia
20%
Clinical Oncology
20%
Argipressin
20%
Cancer Research
20%
Small Interfering RNA
20%
Pancreas Tumor
20%
Conjugate
20%
Glucose Tolerance
20%
Pancreas Adenocarcinoma
20%
Reactive Oxygen Species
14%
Xenograft
12%
Tumor Model
11%
Adaptive Immunity
10%
Malignant Neoplasm
10%
Liver Injury
10%
Treatment Modality
10%
Glucagon Release
7%
T Lymphocyte
5%
CD8 Antigen
5%
Analysis of Variance
5%
Photochemotherapy
5%
Pancreatic Islet
5%
Endocrine Cell
5%
Radiation Therapy
5%
Maturity Onset Diabetes of the Young
5%
Insulin Deficiency
5%
Patient with Diabetes
5%
Protein Expression
5%
Immunology and Microbiology
Programmed Death-Ligand 1
40%
Immune Checkpoint Inhibitor
29%
Vasopressin
20%
Secretory Cell
20%
Arginine Vasopressin
20%
Adaptive Immune System
13%
CD8
7%
CD4
7%
Microbubble
7%
T Cell
7%
Tumor Immunity
5%
Sensitization
5%
Cell Death
5%
Intravenous Immunoglobulin
5%
Monoclonal Antibody
5%
Tumor Volume
5%
Programmed Cell Death
5%
